← Leaderboards
Yuwen Zhu
University Of Colorado Denver
$3,496,594
Attributed
$3,496,594
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2022–25$2M$1.5M$1M$500K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$3,496,594 · 3
By mechanism
R01$3,496,594 · 3
Top collaborators
No co-investigators on record.
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Eduardo Davila$8,435,659
- Mayumi Fujita$5,471,263
- David A. Norris$7,265,873
- Antonio Jimeno$15,496,689
- Raul Martin Torres$14,543,594
Others in their field
Other Rising Stars on “Tumor”
- Kenneth Schultz · Trethera Corporation$7,146,643
- Jeff P Simko · Washington University$4,848,843
- Gary G Schwartz · University Of North Dakota$4,000,000
- Yicheng Wang · Immunova Therapeutics, Llc$4,000,000
- David G Brooks · Boston Immune Technologies And Therapeutics, Inc.$3,974,764
- Daniel Francis · Claria Medical, Inc.$3,708,259
Research focus
TumorPathway InteractionsMolecularCancer ImmunotherapyImmunotherapyLigandsT-LymphocyteTumor MicroenvironmentMalignant NeoplasmsMelanomaImmunologicsFunctional DisorderInfiltrationBindingMonoclonal AntibodiesNovel StrategiesCancer TypeCancer TherapyAnti-Pd1 TherapyCellsCd8-Positive T-LymphocytesImmune Checkpoint BlockersImageImmune Function
Grant awards (10)
The CD93 pathway and melanoma therapy$355,706
R01 · FY2025 · CA · contact PI
The GPR171 pathway in cancer immunotherapy$355,706
R01 · FY2025 · CA · contact PI
Melanoma Immunotherapy with GPR182 blockade$355,706
R01 · FY2025 · CA · contact PI
Melanoma Immunotherapy with GPR182 blockade$337,922
R01 · FY2024 · CA · contact PI
The CD93 pathway and melanoma therapy$337,922
R01 · FY2024 · CA · contact PI
The GPR171 pathway in cancer immunotherapy$337,922
R01 · FY2024 · CA · contact PI
The GPR171 pathway in cancer immunotherapy$355,706
R01 · FY2023 · CA · contact PI
Melanoma Immunotherapy with GPR182 blockade$355,706
R01 · FY2023 · CA · contact PI
The CD93 pathway and melanoma therapy$348,592
R01 · FY2023 · CA · contact PI
The CD93 pathway and melanoma therapy$355,706
R01 · FY2022 · CA · contact PI